Your browser doesn't support javascript.
loading
Prognostic Impact and Late Evolution of Untreated Moderate (2/4+) Functional Tricuspid Regurgitation in Patients Undergoing Aortic Valve Replacement.
Taramasso, Maurizio; Maisano, Francesco; De Bonis, Michele; Pozzoli, Alberto; Schiavi, Davide; Benussi, Stefano; Grimaldi, Antonio; La Canna, Giovanni; Alfieri, Ottavio.
Afiliação
  • Taramasso M; Klinik für Herz- und Gefässchirurgie, UniversitätsSpital Zürich, Zürich, Switzerland.
  • Maisano F; Klinik für Herz- und Gefässchirurgie, UniversitätsSpital Zürich, Zürich, Switzerland.
  • De Bonis M; Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
  • Pozzoli A; Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
  • Schiavi D; Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
  • Benussi S; Klinik für Herz- und Gefässchirurgie, UniversitätsSpital Zürich, Zürich, Switzerland.
  • Grimaldi A; Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
  • La Canna G; Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
  • Alfieri O; Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
J Card Surg ; 31(1): 9-14, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26549799
OBJECTIVES: The aim of the present study was to evaluate the prognostic impact and late evolution of associated tricuspid regurgitation (TR) 2/4+ after aortic valve replacement (AVR). METHODS: We evaluated 61 patients who underwent AVR between 2003 and 2012 (35 for aortic stenosis [AS], 26 for aortic regurgitation [AR]) with associated untreated TR 2/4+. Patients with concomitant mitral disease were excluded. Median follow-up was 3.2 years. Serial echocardiographic and clinical data were collected and analyzed. RESULTS: Mean age was 65 ± 13 years; 26% of the patients were in NYHA class III-IV. Left ventricular ejection fraction was 53 ± 11%. Comorbidity included: chronic obstructive pulmonary disease in 5%, chronic renal failure in 13%, coronary artery disease in 20%, history of stroke/TIA in 8%. Thirty-day mortality was 1.6%. Overall actuarial survival was 83 ± 6% at 6.5 years, with a freedom from cardiac death of 90 ± 5%. Freedom from TR ≥3+ was 86 ± 6% at 6.5 years. At last follow-up, 82% of the patients had TR 0-1/4+, 9% had TR 2/4+, 4.5% had TR 3/4+ and 4.5% had TR 4/4+. Occurrence of TR ≥ 3+ at follow-up was associated with increased cardiac mortality (HR 10.5; p = 0.009). CONCLUSIONS: preoperative untreated TR 2/4+ improves or remains stable in the majority of patients. The poor outcomes associated with TR > 2+ suggest the need for better methods to identify subjects at risk for TR progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Valva Aórtica / Insuficiência da Valva Aórtica / Estenose da Valva Aórtica / Insuficiência da Valva Tricúspide / Implante de Prótese de Valva Cardíaca Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Valva Aórtica / Insuficiência da Valva Aórtica / Estenose da Valva Aórtica / Insuficiência da Valva Tricúspide / Implante de Prótese de Valva Cardíaca Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article